Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by Craigbadon Dec 18, 2016 9:47pm
195 Views
Post# 25617536

RE:RE:RE:RE:RE:RE:Email from Fred

RE:RE:RE:RE:RE:RE:Email from FredI won't argue with the science, it may be great. The economics is the standout. Over the years, the company has made alot of big sales estimates for 3-4 years out to keep shareholders biting but hasn't delivered on any of them. Those who bought 3-4 years ago expecting over $100 million in sales this year are likely dissappointed. The problem comes when the company keeps issuing equity, the share count keeps getting bigger, the market cap keeps getting bigger, so the promises of absolutely huge sales numbers for 3-4 years out become almost impossible to live up to to justify another few years of cash burn.  If they have been diluting by 19% per year historically and are still years away from generating significant revenue, when compounded the shares o/s will rise so much the price per share should actually go down unless the estimates actually keep getting bigger, which they always do, but none have ever been delivered upon. The cycle eventually comes to an end.

stockbuphoon wrote: CraigBad, 

I am not sure you have strong readers comprehension, I guess, but I would take the patent offices, FDA reviews and some heavyweight scientific experts in their respective fields over a BloomBurton analyst and an anonymous coward twisting words and writing lies on a site well known to be used for exactly these misinformation attacks promoted by hedge funds.

The wait has been long and we have definitely paid in share count with threats of bankruptcy that no one will deny here but PLI is finally at revenue accelerated growth stage and a much different place than 2008, etc. It cannot even be compared. Even with high discount rates, the numbers workforce substantial growth in share price work. You obviously have done no recent due dil.


Bullboard Posts